# Human Hindbrain Organoid Functional Assay Services. Canonical: https://abierto.us/opportunities/rfqcdr2026135968 - Solicitation number: RFQ_CDR-2026-135968 - Notice type: Combined synopsis and solicitation - Status: Open. Offers due September 17, 2026 at 10:30 AM EDT - Department: Department of Health and Human Services - Agency: Food and Drug Administration - Contracting office: FDA Office of Acq Grant SVCS (75F401) - NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology) - Product or service code: B504 Chemical/Biological Studies and Analysis - First posted: September 11, 2026 - Last posted: September 11, 2026 - SAM.gov: https://sam.gov/workspace/contract/opp/0a2d3e56451c4afa948835a62000bb09/view ## Description The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Division of Applied Regulatory Science (DARS), intends to award a sole-source, Firm-Fixed-Price purchase order to OrganoTherapeutics SARL for Human iPSC-Derived Hindbrain Organoid Functional Assay Services. The requirement includes the provision of human induced pluripotent stem cell (iPSC)-derived hindbrain organoids and associated materials necessary to support in vitro research evaluating drug-induced effects on respiratory-relevant neural circuits. The contractor will also perform functional characterization of the organoids using three-dimensional multi-electrode array (3D MEA) technology to assess electrophysiological responses to drugs known to affect respiratory function. The functional characterization includes testing FDA-identified drug and reversal-agent combinations, MEA measurements, evaluation of batch-to-batch reproducibility, collection of exposed drug solutions for FDA verification, data analysis, and delivery of raw data, analyzed data, analysis files, and study reports. The requirement also includes twelve scheduled deliveries of human hindbrain organoids to the FDA White Oak Campus. The first delivery will consist of 96 organoids, with subsequent deliveries consisting of 48 organoids each. Functional characterization will be performed at the contractor's laboratory. The anticipated period of performance is eighteen (18) months from the date of award. This acquisition is being conducted as a commercial service acquisition under RFO FAR Part 12. The Government's decision to restrict competition is documented pursuant to RFO FAR 12.102(a). Market research identified OrganoTherapeutics SARL as the only source capable of satisfying the Government's complete requirement for both the required human hindbrain organoids and associated functional assay services. This notice is not intended to restrict consideration of any responsible source capable of meeting the Government's complete requirement. All responsible sources may submit a quotation and supporting capability information by the response date identified in this notice. Any timely response demonstrating the capability to satisfy the Government's complete requirement will be considered by the Contracting Officer prior to award. NAICS: 541714 PSC: B504 – Special Studies/Analysis – Chemical/Biological Place of Delivery: FDA White Oak Campus, Silver Spring, Maryland Place of Service Performance: Contractor's laboratory ## Attachments - [Solicitation_CDER-2026-135969.pdf](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/7db698374b504a50ac9d642cf5ac1198/download) ## Publications - September 11, 2026: Combined synopsis and solicitation, due September 17, 2026 at 10:30 AM EDT. Notice 0a2d3e56451c4afa948835a62000bb09. https://sam.gov/workspace/contract/opp/0a2d3e56451c4afa948835a62000bb09/view ## Points of contact - Iris Johnson, Iris.Johnson1@fda.hhs.gov, 3017963353 - L. Maria Finan, Linda.Finan@fda.hhs.gov, 2404025712 --- Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/rfqcdr2026135968.